Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMB-06 in relapsed or refractory multiple myeloma
NCT04735575Phase 2Terminated
- Sponsor
- EpimAb Biotherapeutics
- Start
- May 2021
- Primary completion
- Aug 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of cizutamig in multiple myeloma (MM), sponsored by EpimAb Biotherapeutics. Started May 2021; status: terminated.
02
Drugs
cizutamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04735575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04735575.